Summary
The provided text contains multiple claims about Entresto/generic substitution, but it only supplied FDA label excerpts related to fetal toxicity/pregnancy. No subset of the claims can be verified against the supplied label excerpts, so label-alignment cannot be meaningfully scored.
Category Scores
Accurate Statements
Unsupported Statements
Entresto is a fixed-dose combination medicine.
No label excerpt provided in the prompt supports this statement.
Entresto contains sacubitril and valsartan.
No label excerpt provided in the prompt supports this statement (the prompt provides label sections only for fetal toxicity/pregnancy).
The generic for Entresto is a drug product with the same active ingredients in the same combination and strengths: sacubitril + valsartan.
The supplied label excerpts do not address generic composition.
In the U.S., the generic product is typically marketed under the combination active-ingredient name "sacubitril/valsartan".
The supplied label excerpts do not address marketing nomenclature for generics.
Brand-to-generic switches should use the same strength and dosing form (for example, the mg strengths and tablet type).
The supplied label excerpts do not provide guidance on brand-to-generic switching or equivalence by dosing form.
Whether a generic is available can depend on FDA approvals and the specific strength.
The supplied label excerpts do not address generic availability.
If a pharmacy shows no generic for one dose, another strength might be available, or the pharmacy may need to order it.
The supplied label excerpts do not address pharmacy dispensing logistics.
To avoid dosing changes, confirm that the replacement is the same combination (sacubitril/valsartan) and the same strength as current Entresto tablets.
The supplied label excerpts do not provide instructions for substitution.
If Entresto is taken for heart failure, dosing schedule instructions from the clinician should be kept.
The supplied label excerpts do not include dosing instructions or heart failure dosing schedule guidance.
Contradictions
Important Omissions
If evaluating the fetal toxicity/pregnancy warning, the response should explicitly state the label-supported warnings (e.g., ENTRESTO can cause fetal harm; discontinue when pregnancy is detected; counseling/serial ultrasound/close neonatal observation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
Because the supplied label excerpts concern fetal toxicity/pregnancy, but the claims provided are primarily about generic substitution and dosing-schedule retention (which are not supported by the supplied label excerpts), the label-based safety alignment cannot be established from provided evidence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Most claims cannot be verified against the provided FDA label excerpts (which focus only on fetal toxicity/pregnancy).
Suggested Improvement
Restrict claims to the supplied label content (Boxed Warning/5.1/8.1/17) when performing label alignment, or provide the full prescribing information sections needed to verify substitution and dosing guidance.